Company Pangaea Oncology, S.A.

Equities

PANG

ES0105221008

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Pangaea Oncology, S.A.

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed BME Other stock markets 10:00:06 2024-04-25 am EDT			5-day change	1st Jan Change
1.71 ^EUR	0.00%		-3.93%	-7.07%

2023	Pangaea Oncology, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	Pangaea Oncology, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	CI

Pangaea Oncology SA is a Spain-based company primarily engaged in the biotechnology sector. The Company focuses on the development of oncology treatments. The Companyâs activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.

Number of employees: 58

EUR in Million	2021	Weight	2022	Weight	Delta
Care Management 76.6 %	2	53.2 %	3	76.6 %	+36.57%
Services to Enterprises 23.4 %	2	46.8 %	1	23.4 %	-52.50%

EUR in Million	2021	Weight	2022	Weight	Delta
Spain 87.2 %	3	70.0 %	4	87.2 %	+18.14%
Others 10.5 %	1	15.0 %	0	10.5 %	-33.49%
Other European Union Countries 2.3 %	1	15.0 %	0	2.3 %	-85.41%

Managers	Title	Age	Since
Santiago Ramon y Cajal FOU	Founder	-	06-12-31
Rafael Rosell Costa FOU	Founder	-	06-12-31
Javier Rodríguez Rivela FOU	Founder	-	06-12-31
Alejandro García Moncayo DFI	Director of Finance/CFO	-	-
Fermín Goytisolo PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Javier Rodríguez Rivela FOU	Founder	-	06-12-31
Rafael Rosell Costa FOU	Founder	-	06-12-31
Santiago Ramon y Cajal FOU	Founder	-	06-12-31
Jose Maestre FOU	Founder	-	-
Luis Barcelona Escartin BRD	Director/Board Member	-	-
Rafael López-Diéguez BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	30,489,770	6,427,594 ( 21.08 %)	1,044,030 ( 3.424 %)	21.08 %

Name	Equities	%	Valuation
Indumenta Pueri SL 13.83 %	4,215,975	13.83 %	8 M €
Vidaro Inversiones SL 8.233 %	2,510,206	8.233 %	5 M €
Mirling Europe SL 6.550 %	1,997,080	6.550 %	4 M €
Asin Carlos Gustavo Genzor 6.550 %	1,997,080	6.550 %	4 M €
Electrica Del Oeste SL 6.340 %	1,933,051	6.340 %	4 M €
Direct Investments SL 6.230 %	1,899,513	6.230 %	4 M €
Inversiones Industriales Serpis SL 5.912 %	1,802,662	5.912 %	4 M €
Ideas de Bombero SL 5.757 %	1,755,342	5.757 %	4 M €
Rafael Rosell Costa 5.491 %	1,674,222	5.491 %	3 M €
Inversiones Orensanas de Patrimonio SL 5.476 %	1,669,715	5.476 %	3 M €

Pangaea Oncology SA

5-19, Carrer de Sabino Arana

08028, Barcelona

+34 93 409 79 81

http://www.panoncology.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
PANGAEA ONCOLOGY, S.A.	-7.07%	53.94M
IQVIA HOLDINGS INC.	+1.48%	42.59B
MODERNA, INC.	+7.92%	40.65B
LONZA GROUP AG	+48.66%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+7.94%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.76%	18.17B
MEDPACE HOLDINGS, INC.	+29.12%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.70%	11.7B
UNITED THERAPEUTICS CORPORATION	+7.23%	11.1B

Other Biotechnology & Medical Research